The UBI alumni Lipigon Pharmaceuticals announced yesterday that the startup has entered into a target validation research agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals. The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.
Lipigon Pharmaceuticals, an Umeå University spin-off and UBI alumni company has attracted two top talents to join the work in their board. Gisela Sitbon is nominated for the position as Chairman of the Board.
The eight consecutive Biotech Umeå Investment Day attracted almost 30 Swedish and international investors to Blasierummet at Grand Hotel on the 2 of February 2017 in Stockholm. One of the most appreciated aspects of the event was the flexibility to arrange additional ad-hoc partnering meetings and the size and atmosphere at the event.